The Discovery of Asunaprevir (BMS-650032), An Orally Efficacious NS3 Protease Inhibitor for the Treatment of Hepatitis C Virus Infection
Paul M. Scola(Bristol-Myers Squibb (United States)), Jialong Zhu(Bristol-Myers Squibb (United States)), Luciano Mueller(Bristol-Myers Squibb (United States)), Barbara Zheng(Bristol-Myers Squibb (United States)), Anthony J. Cocuzza(Bristol-Myers Squibb (United States)), Jay O. Knipe(Bristol-Myers Squibb (United States)), Paul Falk(Bristol-Myers Squibb (United States)), Hong Shi(Bristol-Myers Squibb (United States)), Maria Donoso(Bristol-Myers Squibb (United States)), Li‐Qiang Sun(Bristol-Myers Squibb (United States)), Steven M. LeVine(Kaiser Permanente Oakland Medical Center), Jacques Friborg(Bristol-Myers Squibb (United States)), Paul Lévesque(Bristol-Myers Squibb (United States)), Donna M. Bilder(Bristol-Myers Squibb (United States)), Huabin Sun(Bristol-Myers Squibb (United States)), Richard J. Colonno(Assembly Biosciences (United States)), Tatyana Zvyaga(Bristol-Myers Squibb (Germany)), Richard Schartman(Bristol-Myers Squibb (Germany)), Herbert E. Klei(Bristol-Myers Squibb (United States)), Qi Gao(Merck & Co., Inc., Rahway, NJ, USA (United States)), Piyasena Hewawasam(Bristol-Myers Squibb (United States)), Stanley V. D’Andrea(Bristol-Myers Squibb (United States)), Guangzhi Zhai(Bristol-Myers Squibb (United States)), Diana Barry(Bristol-Myers Squibb (United States)), Danshi Li(Montreal Heart Institute), Alan Xiangdong Wang(Bristol-Myers Squibb (United States)), Ramkumar Rajamani(Bristol-Myers Squibb (United States)), Brian L. Venables(Bristol-Myers Squibb (United States)), Jeffrey Tredup(Bristol-Myers Squibb (United States)), Michael Sinz(Rutgers, The State University of New Jersey), Fei Yu(Yunnan Academy of Agricultural Sciences), Kevin Kish(Bristol-Myers Squibb (United States)), Dennis Hernandez(Bristol-Myers Squibb (United States)), Amy K. Sheaffer(Bristol-Myers Squibb (United States)), Jie Chen(Bristol-Myers Squibb (United States)), Yan Chen(Zhengzhou University), Ny Sin(Bristol-Myers Squibb (United States)), Chaoqun Chen(Bristol-Myers Squibb (United States)), Stephen P Adams(Bristol-Myers Squibb (United States)), Yong Qiang Tu(Lanzhou University), Yong–Hae Han(Bristol-Myers Squibb (United States)), Andrew C. Good(Bristol-Myers Squibb (United States)), Dennis M. Grasela(Bristol-Myers Squibb (United States)), James Loy(Bristol-Myers Squibb (United States)), Kathy Mosure(Bristol-Myers Squibb (United States)), Sing‐Yuen Sit(Bristol-Myers Squibb (United States)), William Warner(Bristol-Myers Squibb (United States))
Cited by 112
Related Papers
Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect
|Nature|2010|940
Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy #
|Hepatology|2009|815
CYP3A4 Induction by Drugs: Correlation between a Pregnane X Receptor Reporter Gene Assay and CYP3A4 Expression in Human Hepatocytes
|Drug Metabolism and Disposition|2002|447
Entecavir for Treatment of Lamivudine-Refractory, HBeAg-Positive Chronic Hepatitis B
|Gastroenterology|2006|414
Effects of Experimental Heart Failure on Atrial Cellular and Ionic Electrophysiology
|Circulation|2000|373